Zevra Therapeutics (ZVRA) continues to build momentum in Q1 2025, demonstrating exceptional growth and signaling significant upside potential. Amid a surge in quarterly revenue up nearly 500% year‑over‑year and improved losses, analysts are rapidly raising earnings and price targets. In this article we will dive into Zevra Therapeutics recent earnings, stock performance & valuation, growth potential, and the risks investor should consider.
Seeking Undervalued Stocks With Great Future Growth in the US Stock Market